Navigation Links
FDA Approves Redesigned Labels for Some Merck Drugs
Date:6/10/2011

SILVER SPRING, Md., June 10, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today is announcing the approval of Merck's redesigned drug container labels that include a new standardized format to improve readability and provide better information on product and strength differentiation.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Merck's Label Standardization Project includes the revision of 34 container labels for 16 solid oral drug products regulated by the FDA's Center for Drug Evaluation and Research (CDER). Drugs affected by the revisions include: Cozaar, Crixivan, Hyzaar, Isentress, Janumet, Januvia, Mevacor, Noroxin, Prinivil, Prinizide, Propecia, Proscar, Singulair, Zocor, and Zolinza.

"We commend Merck for their efforts," said Janet Woodcock, M.D., director of CDER. "This was no small undertaking, and we are hopeful that Merck's new standardized labels will aid in reducing pharmacy selection errors."

Merck's project included evaluating the proposed label content and layout, selecting new packaging design, and obtaining regulatory approval to implement the new packaging design. The Label Standardization Project process included:

  • a scientific approach to label design through Human Factors Engineering and Usability Studies;
  • incorporation of feedback received from the FDA and from label surveys;
  • a bundled supplement regulatory approach to ensure that labels were acceptable across CDER's eight clinical divisions.

To better access the impact of these label changes, the FDA encourages health care providers to report medication errors related to the products included in Merck's Label Standardization Project to MedWatch, the FDA's adverse event reporting program.

For more information:

MedWatch, the FDA's adverse event reporting program

http://www.fda.gov/Safety/MedWatch/default.htm

How to Report a Medication Error

http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Morgan Liscinsky, 301-796-0379, morgan.liscinsky@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... May 22, 2017  Lilac Corp, the company ... the launch of a new website . ... of a clinical study that showed surprising clearance ... Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, precancerous, ... there are no other treatments that clear the ...
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... -- Amy Baxter MD, chief executive officer and founder of ... was awarded a 2017 Top 40 Healthcare Transformer designation ... the MM&M Top 40 Healthcare Transformers dinner and awards ... May 10, 2017. The dinner followed a full-day conference ... pill."  "Innovation goes beyond invention," noted Baxter ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... ... the Garden of Eden”: retells the stories of three Bible figures in modern terms. ... Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born in 1953 ... they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, she toured ...
(Date:5/26/2017)... ... 26, 2017 , ... Water damage to the flooring of several classrooms at ... education officials with a number of critical issues to address before students could return ... accomplished with little or no disruption to class schedules. Second, the project had to ...
(Date:5/24/2017)... ... 24, 2017 , ... In modern research, success depends greatly ... for research and understanding the basic principles that were designed to drive that ... in stereo microscopy for brightfield and fluorescence typically used in laboratories working on ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., a leader in ... a one-day technology conference in San Diego, CA. , At nVerge 2017, Altec ... fully utilize and enhance their Sage ERP solutions by providing improved visibility and control ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... dental implants in Bayside, NY, who have now spent 10 years as clinical ... New York University (NYU) College of Dentistry. Through the program, private practitioners receive ...
Breaking Medicine News(10 mins):